We have located links that may give you full text access.
Cumulative Incidence and Predictors of Progression in Corticosteroid-Naïve Patients with Sarcoidosis.
PloS One 2015
BACKGROUND: Assessment of the clinical course of sarcoidosis requires long-term observation. However, the appropriate period of follow-up for sarcoidosis remains unclear, especially in patients without indication of corticosteroid therapy at the time of diagnosis.
OBJECTIVE: This study aimed to clarify the cumulative incidence and identify risk factors for disease progression in corticosteroid-naïve sarcoidosis patients.
METHODS: The clinical courses of 150 Japanese patients with sarcoidosis, who were followed for more than 2 years and had no indication for corticosteroid therapy at diagnosis, were retrospectively reviewed. Disease progression was defined as worsening of pulmonary sarcoidosis, development of new organ involvement, or extrapulmonary organ damage. The cumulative incidence of progression was estimated by generating a cumulative incidence curve with the Fine and Gray method.
RESULTS: The median follow-up duration was 7.7 years (interquartile range, 4.7-13.6 years). Thirty-two (21%) patients experienced disease progression. New organ involvement appeared in 16 patients (11%). The 6-month, and 1-, 5-, 10-, and 15-year cumulative incidence of progression was 2%, 5%, 15%, 28%, and 31%, respectively. The number of organs involved at diagnosis was an independent predictor for progression with a multifactorial adjusted hazard ratio of 1.71 (95% confidence interval, 1.11-2.62). The optimal cut-off of the number of organs involved at diagnosis to identify future progression was three.
CONCLUSIONS: In corticosteroid-naïve sarcoidosis patients, the risks of disease progression are comparable from 0-5 years and 5-10 years after diagnosis. The number of organs involved at diagnosis is a useful predictor for progression of sarcoidosis.
OBJECTIVE: This study aimed to clarify the cumulative incidence and identify risk factors for disease progression in corticosteroid-naïve sarcoidosis patients.
METHODS: The clinical courses of 150 Japanese patients with sarcoidosis, who were followed for more than 2 years and had no indication for corticosteroid therapy at diagnosis, were retrospectively reviewed. Disease progression was defined as worsening of pulmonary sarcoidosis, development of new organ involvement, or extrapulmonary organ damage. The cumulative incidence of progression was estimated by generating a cumulative incidence curve with the Fine and Gray method.
RESULTS: The median follow-up duration was 7.7 years (interquartile range, 4.7-13.6 years). Thirty-two (21%) patients experienced disease progression. New organ involvement appeared in 16 patients (11%). The 6-month, and 1-, 5-, 10-, and 15-year cumulative incidence of progression was 2%, 5%, 15%, 28%, and 31%, respectively. The number of organs involved at diagnosis was an independent predictor for progression with a multifactorial adjusted hazard ratio of 1.71 (95% confidence interval, 1.11-2.62). The optimal cut-off of the number of organs involved at diagnosis to identify future progression was three.
CONCLUSIONS: In corticosteroid-naïve sarcoidosis patients, the risks of disease progression are comparable from 0-5 years and 5-10 years after diagnosis. The number of organs involved at diagnosis is a useful predictor for progression of sarcoidosis.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app